Lytix Biopharma Investor Relations Material
Latest events
Q1 2025
Lytix Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lytix Biopharma
Access all reports
Lytix Biopharma is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company specializes in using oncolytic peptides, which are designed to kill cancer cells and stimulate the immune system to generate a strong, systemic T-cell response. This approach aims to overcome the challenges of tumor heterogeneity, where variations in cancer cells within a tumor reduce the effectiveness of conventional immunotherapies. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.
Key slides for Lytix Biopharma
Q2 2024
Lytix Biopharma
Q2 2024
Lytix Biopharma
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
LYTIX
Country
🇳🇴 Norway